Can antihypertensive medication contribute to clinically important hypotension in older adults?

For an 83-year-old man, antihypertensive therapy can be an important, modifiable contributor to symptomatic or clinically consequential low blood pressure. The concern is strongest when low readings, orthostatic symptoms, syncope, frailty, or falls coexist, but medication should be reviewed alongside other causes of hypotension.

Clinical evidence

• Across 58 randomized trials including 280,638 participants, antihypertensive treatment nearly doubled hypotension risk versus control (RR 1.97, 95% CI 1.67–2.32) and increased syncope (RR 1.28, 95% CI 1.03–1.59). These are clinically meaningful events, although this analysis did not show a statistically clear increase in falls.
• Risk varies by drug class. Beta-blockers have substantially increased odds of orthostatic hypotension; alpha-blockers are also implicated, while diuretics can contribute through volume depletion.

Post-episode treatment decisions

• Continuing the same blood-pressure-lowering exposure after a hypotensive episode is a plausible driver of recurrent low BP, particularly in adults aged ≥80 years with systolic BP <120 mmHg, severe orthostatic hypotension, or high frailty.
• Direct evidence quantifying recurrent hypotension after a defined episode is limited. In OPTIMISE, withdrawing one drug in adults ≥80 with controlled systolic BP produced a modest systolic-BP increase while maintaining noninferior short-term BP control; serious adverse events did not differ significantly.

Practical implications

• Measure BP seated/supine and after standing; orthostatic hypotension is a ≥20-mmHg systolic or ≥10-mmHg diastolic fall on standing.
• Review symptoms, regimen intensity, each drug’s indication, and concurrent contributors. When reduction is appropriate, changes are generally made one medicine at a time with monitoring and capacity to restart.

Bottom line

• Antihypertensives are a well-supported cause of clinically important hypotension and syncope in older adults. Continued treatment after an episode is a credible concern, warranting prompt individualized reassessment rather than automatic continuation or universal discontinuation.